ANTI-DLL3 ANTIBODIES AND USES THEREOF

Smart overview of the Invention

The disclosed subject matter focuses on antibodies that target DLL3, a protein associated with high-grade pulmonary neuroendocrine tumors of the lung (LU-NETs). These tumors include various types such as typical carcinoid, atypical carcinoid, large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC). The antibodies are designed to bind specifically to DLL3, facilitating potential therapeutic applications.

Background of the Invention

DLL3 is prominently expressed in aggressive lung tumors like SCLC and LCNEC, which are often linked to poor prognosis and higher incidence in smokers. These tumors exhibit overlapping survival curves and are biologically aggressive. Despite surgical interventions, survival rates remain low, emphasizing the need for targeted therapies. Targeting DLL3 with specific antibodies could provide a novel approach to treat these challenging cancer types.

Summary of the Invention

The invention describes antibodies or antigen-binding fragments that specifically target DLL3. These molecules have a high degree of sequence homology or identity with specific amino acid sequences detailed in the application. The antibodies are designed to recognize and bind DLL3 with high specificity, which could be leveraged for therapeutic purposes.

Antibody Characteristics

The antibodies feature heavy and light chain variable regions with amino acid sequences exhibiting varying degrees of homology or identity to specified sequences. The heavy chain sequences range from SEQ ID NO: 7 to SEQ ID NO: 172, while the light chain sequences range from SEQ ID NO: 8 to SEQ ID NO: 173. These sequences are critical for the binding specificity and efficacy of the antibodies against DLL3.

Potential Applications

These anti-DLL3 antibodies can be utilized in therapeutic strategies targeting DLL3-expressing tumors. By binding specifically to DLL3, these antibodies may interfere with tumor growth or progression, providing a targeted treatment option for patients with high-grade pulmonary neuroendocrine tumors, particularly those resistant to conventional therapies.